€4m donated to university for breast cancer research

€4m donated to university for breast cancer research

The University of Galway is receiving €4 million in funding from the National Breast Cancer Research Institute to improve research and diagnostics as well as more clinical trials for breast cancer patients.

University gets €4m investment for life-changing research into breast cancer

The initiative will see the investment by National Breast Cancer Research Institute to the University of Galway.

Donation of €4m to UG will support "life-changing" breast cancer research - Connacht Tribune - Galway City Tribune

This article first appeared on Galway Bay FM Funding of €4m has been donated towards breast cancer research at the Lambe Institute at UHG. The philanthropy from the National Breast Cancer Research Institute will cover a range of advancements and benefits. They include digital imaging currently unavailable in Ireland, expansion of clinical trials, and more international collaboration. The research will be carried out at the Lambe Institute, which…

Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant

18F-FDG PET/CT-Based Deep Radiomic Models for Enhancing Chemotherapy Response Prediction in Breast Cancer

Background Enhancing the accuracy of tumor response predictions enables the development of tailored therapeutic strategies for patients with breast cancer. In this study, we developed deep-radiomic models to enhance the prediction of chemotherapy response after the first treatment cyc...

New hope for patients with breast cancer gene

(BBC) – A new treatment approach can significantly improve survival rates for patients with aggressive, inherited breast cancer, a study suggests. The trial, led by Addenbrooke’s Hospital in Cambridge, and published in Nature Communications, involved women with early-stage breast cancer who have inherited BRCA1 or BRCA2 gene mutations. Giving them the targeted drug olaparib before surgery greatly reduced the chances of the cancer coming back. (R…